These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 15325612)

  • 1. In-transit melanoma: the role of alkylating-agent resistance in regional therapy.
    Grubbs EG; Abdel-Wahab O; Cheng TY; Abdel-Wahab Z; Peterson B; Pruitt SK; Colvin OM; Friedman HS; Tyler DS
    J Am Coll Surg; 2004 Sep; 199(3):419-27. PubMed ID: 15325612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of resistance to regional chemotherapy in the extremity melanoma model.
    Grubbs EG; Ueno T; Abdel-Wahab O; Cheng TY; Pruitt SK; Michael Colvin O; Friedman HS; Tyler DS
    Surgery; 2004 Aug; 136(2):210-8. PubMed ID: 15300182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cross-resistance and glutathione-S-transferase-pi levels among four human melanoma cell lines selected for alkylating agent resistance.
    Wang YY; Teicher BA; Shea TC; Holden SA; Rosbe KW; al-Achi A; Henner WD
    Cancer Res; 1989 Nov; 49(22):6185-92. PubMed ID: 2804968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A human melanoma xenograft in a nude rat responds to isolated limb perfusion with TNF plus melphalan.
    Bauer TW; Gutierrez M; Dudrick DJ; Li J; Blair IA; Menon C; Fraker DL
    Surgery; 2003 Apr; 133(4):420-8. PubMed ID: 12717360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolism of melphalan by rat liver microsomal glutathione S-transferase.
    Zhang J; Ye Z; Lou Y
    Chem Biol Interact; 2005 Apr; 152(2-3):101-6. PubMed ID: 15840383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US.
    Beasley GM; Caudle A; Petersen RP; McMahon NS; Padussis J; Mosca PJ; Zager JS; Hochwald SN; Grobmyer SR; Delman KA; Andtbacka RH; Noyes RD; Kane JM; Seigler H; Pruitt SK; Ross MI; Tyler DS
    J Am Coll Surg; 2009 May; 208(5):706-15; discussion 715-7. PubMed ID: 19476821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isolated limb perfusion with melphalan and tumor necrosis factor alpha for advanced melanoma and soft-tissue sarcoma.
    Hayes AJ; Neuhaus SJ; Clark MA; Thomas JM
    Ann Surg Oncol; 2007 Jan; 14(1):230-8. PubMed ID: 17066234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of glutathione conjugation of melphalan in the isolated in situ liver perfusion in humans.
    Vahrmeijer AL; Snel CA; Steenvoorden DP; Beijnen JH; Pang KS; Schutrups J; Tirona R; Keizer HJ; van Dierendonck JH; van de Velde CJ; Mulder GJ
    Cancer Res; 1996 Oct; 56(20):4709-14. PubMed ID: 8840988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isolated limb perfusion for malignant melanoma.
    Alexander HR; Fraker DL; Bartlett DL
    Semin Surg Oncol; 1996; 12(6):416-28. PubMed ID: 8914206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of repeat isolated limb perfusions with tumor necrosis factor alpha and melphalan for multiple in-transit metastases in patients with prior isolated limb perfusion failure.
    Grünhagen DJ; van Etten B; Brunstein F; Graveland WJ; van Geel AN; de Wilt JH; Eggermont AM
    Ann Surg Oncol; 2005 Aug; 12(8):609-15. PubMed ID: 15968498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive factors of regional toxicity and serum creatine phosphokinase levels after isolated limb infusion for melanoma: a multi-institutional analysis.
    Santillan AA; Delman KA; Beasley GM; Mosca PJ; Hochwald SN; Grobmyer SR; Andtbacka RH; Noyes RD; Kane JM; Ross MI; Tyler DS; Zager JS
    Ann Surg Oncol; 2009 Sep; 16(9):2570-8. PubMed ID: 19543771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repeat isolated limb perfusion with TNFalpha and melphalan for recurrent limb melanoma after failure of previous perfusion.
    Noorda EM; Vrouenraets BC; Nieweg OE; van Geel AN; Eggermont AM; Kroon BB
    Eur J Surg Oncol; 2006 Apr; 32(3):318-24. PubMed ID: 16412605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microdialysis and response during regional chemotherapy by isolated limb infusion of melphalan for limb malignancies.
    Thompson JF; Siebert GA; Anissimov YG; Smithers BM; Doubrovsky A; Anderson CD; Roberts MS
    Br J Cancer; 2001 Jul; 85(2):157-65. PubMed ID: 11461070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors predictive of acute regional toxicity after isolated limb infusion with melphalan and actinomycin D in melanoma patients.
    Kroon HM; Moncrieff M; Kam PC; Thompson JF
    Ann Surg Oncol; 2009 May; 16(5):1184-92. PubMed ID: 19224289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brostallicin, a novel anticancer agent whose activity is enhanced upon binding to glutathione.
    Geroni C; Marchini S; Cozzi P; Galliera E; Ragg E; Colombo T; Battaglia R; Howard M; D'Incalci M; Broggini M
    Cancer Res; 2002 Apr; 62(8):2332-6. PubMed ID: 11956092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo isolated kidney perfusion with tumour necrosis factor alpha (TNF-alpha) in tumour-bearing rats.
    van der Veen AH; Seynhaeve AL; Breurs J; Nooijen PT; Marquet RL; Eggermont AM
    Br J Cancer; 1999 Feb; 79(3-4):433-9. PubMed ID: 10027309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperthermic isolation limb perfusion with TNFalpha in the treatment of in-transit melanoma metastasis.
    Di Filippo F; Rossi CR; Santinami M; Cavaliere F; Garinei R; Anzà M; Perri P; Botti C; Di Angelo P; Pasqualoni R; Di Filippo S
    In Vivo; 2006; 20(6A):739-42. PubMed ID: 17203758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biochemical characterization of in vivo alkylating agent resistance of a murine EMT-6 mammary carcinoma. Implication for systemic involvement in the resistance phenotype.
    Chen G; Teicher BA; Frei E
    Cancer Biochem Biophys; 1998 Jun; 16(1-2):139-55. PubMed ID: 9923973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic antitumor activity of histamine plus melphalan in isolated limb perfusion: preclinical studies.
    Brunstein F; Hoving S; Seynhaeve AL; van Tiel ST; Guetens G; de Bruijn EA; Eggermont AM; ten Hagen TL
    J Natl Cancer Inst; 2004 Nov; 96(21):1603-10. PubMed ID: 15523089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020.
    Cornett WR; McCall LM; Petersen RP; Ross MI; Briele HA; Noyes RD; Sussman JJ; Kraybill WG; Kane JM; Alexander HR; Lee JE; Mansfield PF; Pingpank JF; Winchester DJ; White RL; Chadaram V; Herndon JE; Fraker DL; Tyler DS;
    J Clin Oncol; 2006 Sep; 24(25):4196-201. PubMed ID: 16943537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.